TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05431179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zilovertamab
Description: After 16 weeks in the open-label Ibrutinib phase, participants will receive zilovertamab (600mg) administered by IV every 2 weeks for 3 administrations and then every 4 weeks thereafter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: All participants will receive oral Ibrutinib (560mg) daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ibrutinib
Description: All participants will receive oral Ibrutinib (560mg) daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: All participants will receive oral Ibrutinib (560mg) daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After 16 weeks in the open-label Ibrutinib phase, participants will receive placebo administered by IV every 2 weeks for 3 administrations and then every 4 weeks thereafter.
Study: NCT04774354

Intervention type: DIAGNOSTIC_TEST
Intervention: POSSUM
Description: These scales will be calculated and compared to the outcomes obtained in our center.
Study: NCT04616235

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab Injectable Product
Description: The intervention group will undergo intense aerobic exercise with prior IL-6R infusion for 1h prior to the exercise bout.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline 0.9% 100 ml NaCl 0.9% will be infused over 1 hour
Description: The control group will undergo intense aerobic exercise with saline infusion for 1h prior to the exercise bout
Study: NCT05171725

Intervention type: DIAGNOSTIC_TEST
Intervention: actigraphy
Description: week long actigraphy assessment with concurrent sleep diary acquisition

Intervention type: DIAGNOSTIC_TEST
Intervention: actigraphy
Description: week long actigraphy assessment with concurrent sleep diary acquisition

Intervention type: DIAGNOSTIC_TEST
Intervention: actigraphy
Description: week long actigraphy assessment with concurrent sleep diary acquisition
Study: NCT06405425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-B01D1
Description: Administration by intravenous infusion for a cycle of 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Study: NCT05192083

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management and Support
Description: A smartphone-based self-management support programme includes a 30-min face-to-face or online session at baseline, 3 phone calls and 2-month mobile messages
Study: NCT05836987

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AFSW Guided DOAC
Description: The AFSW will intermittently and passively assess for rhythm irregularities consistent with AF and notify the wearer and coordinating center if a threshold AF event has occurred.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuous DOAC therapy
Description: DOACs will be prescribed to patients according to the treating healthcare provider(s) according to labeling instructions.
Study: NCT05171725

Intervention type: DIAGNOSTIC_TEST
Intervention: clinician assessment
Description: standard clinical assessment by an expert clinician in the respective field of brain disorders

Intervention type: DIAGNOSTIC_TEST
Intervention: clinician assessment
Description: standard clinical assessment by an expert clinician in the respective field of brain disorders

Intervention type: DIAGNOSTIC_TEST
Intervention: clinician assessment
Description: standard clinical assessment by an expert clinician in the respective field of brain disorders

Intervention type: DIAGNOSTIC_TEST
Intervention: clinician assessment
Description: standard clinical assessment by an expert clinician in the respective field of brain disorders
Study: NCT05208632

Intervention type: OTHER
Intervention: INTERSCALEN BLOCK APPLICATION WITH USG
Description: 40 patients, including ASA1-2, 20 patients over the age of 18, who were planned for upper extremity surgery, in the interscalen group, and 20 in the supraclavicular group, were included in the study. Demographic data of the patients were recorded by measuring PI and PVI values at baseline before the block and at the 1st, 5th, 10th, 15th, and 20th minutes after the block, both simultaneously.

Intervention type: OTHER
Intervention: INTERSCALEN BLOCK APPLICATION WITH USG
Description: 40 patients, including ASA1-2, 20 patients over the age of 18, who were planned for upper extremity surgery, in the interscalen group, and 20 in the supraclavicular group, were included in the study. Demographic data of the patients were recorded by measuring PI and PVI values at baseline before the block and at the 1st, 5th, 10th, 15th, and 20th minutes after the block, both simultaneously.
Study: NCT05783765

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heightened Drive to Eat
Description: Participants' eating rate and eating in the absence of hunger will be assessed during a videotaped experimental meal. The relative reinforcing value of food will be assessed using a computerized behavioral choice task.
Study: NCT05839509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GH001
Description: GH001 administered via inhalation
Study: NCT06067971

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery with augmented reality device
Description: Gynecological laparoscopic surgery with augmented reality device.
Study: NCT05497882

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-Learning Prototype for Dementia Care
Description: Usability testing System Usability Scale
Study: NCT04667429

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food
Description: HEC83518 40mg will be taken orally fasted or with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC83518
Description: HEC83518 will be taken orally before sleep for 15 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC83518
Description: HEC83518 will be taken orally before sleep for 15 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC83518
Description: HEC83518 will be taken orally before sleep for 15 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The placebo will be administered before sleep for 15 days.
Study: NCT05223712

Intervention type: OTHER
Intervention: Diagnostic Test: Chronic Kidney Diseases
Description: The development datasets were used to train the deep learning model, which was validated and tested by the other 4 datasets.

Intervention type: OTHER
Intervention: Diagnostic Test: Chronic Kidney Diseases
Description: The development datasets were used to train the deep learning model, which was validated and tested by the other 4 datasets.
Study: NCT06689098

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetocardiography scan
Description: The MCG system utilizes an array of 64 highly sensitive magnetic sensors known as superconducting quantum interference devices (SQUIDs). These sensors are placed in a shielded environment to reduce interference from external electromagnetic sources. SQUIDs capture variations in the heart's magnetic field throughout the cardiac cycle and correlate these changes with the QRS complex. To filter out electromagnetic noise, several frequency filters are applied. The measurements provide a three-dimensional view of the magnetic field, which is used to generate a composite vector representing the primary electrical axis of the heart. In assessing inflammatory cardiomyopathies, the focus is on the vector associated with the T-wave of the action potential, i.e. the vector from the T-wave beginning to the maximum (T-beg-Tmax interval). A T-wave/MCG vector T-beg-Tmax value ≥ 0.051 has been identified as indicative of pathology, as demonstrated in our previous research.
Study: NCT06006273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Given by vein (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Given by vein (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Given by vein (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Given by vein (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given by vein (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given by vein (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given by vein (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given by vein (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given by PO
Study: NCT06112379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dato-DXd
Description: Experimental drug IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Experimental drug IV Infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: IV Infusion Active comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: IV infusion Experimental/Active Comparator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: IV infusion Experimental/Active Comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: IV Infusion Experimental/Active Comparator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: IV Infusion Experimental/Active Comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: IV infusion Experimental/Active Comparator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: IV infusion Experimental/Active Comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV infusion Experimental/Active Comparator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: IV infusion Experimental/Active Comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion Experimental/Active Comparator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: IV infusion Experimental/Active Comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Tablet Oral route of administration Experimental/Active Comparator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Tablet Oral route of administration Experimental/Active Comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Tablet Oral route of administration Experimental/Active Comparator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olaparib
Description: Tablet Oral route of administration Experimental/Active Comparator
Study: NCT06705998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAR502 single dose
Description: Single oral doses of BAR 502/placebo will be administered as film-coated tablets, in the morning of Day 1, with 150 mL of water, after an overnight fasting of at least 8 hours.~BAR 502 film-coated tablets are available at dose strengths of 3, 10 and 50mg. A maximum of 4 dose levels are pre-planned (3, 10, 30 and 60mg).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo single dose
Description: Matching BAR 502 placebo film-coated tablets will be given to 2 out of 8 subjects in each cohort using the same regimen as outlined for the active study treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAR502 multiple doses
Description: The 2 multiple ascending doses selected based on results of study part A will be administered to 2 study cohorts of 10 subjects each. The IMP will be orally administered once a day from Day 1 to Day 14, at 8:00±1 h, for a total of 14 doses.
Study: NCT04740749

Intervention type: DEVICE
Group type: OTHER
Intervention: Compress Compliant Pre-Stress System
Description: Treatment of malignant femor tumors with the Compress Compliant Pre-Stress System

Intervention type: DEVICE
Group type: OTHER
Intervention: Compress Compliant Pre-Stress System
Description: Treatment of malignant femor tumors with the Compress Compliant Pre-Stress System
Study: NCT05982977

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: The patient was placed in a supine position, selected Lianquan, Fengchi, and acupoints.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation
Description: swallowing training included breathing training, masticatory muscle training, oral movement training and feeding training.
Study: NCT06733025

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tendon lengthening surgery
Description: The participants will first receive BoNT injections, earliest three months after they will undergo tendon lengthening surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BoNT Injections
Description: The dosage and number of injected muscles will vary depending on the degree and extent of spasticity. All patients had previous BoNT injections, one injection circle will be followed in this study.
Study: NCT06737445

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation alone
Description: RTL was performed as a single session using the radiofrequency ablation device (NeuroTherm JK4A; NeuroTherm Ltd, Croydon, London, England).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cortisone Injection
Description: An injection of 1 ml of betamethasone 40 mg/ml and 2 ml of bupivacaine 5 mg/ml was performed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal shock wave therapy
Description: Patients underwent 3 ESWT sessions applied to the plantar heel area, once a week with the same ESWT dose (15 Hz, 2000 pulse, 4.0 bar energy density) using a BTL-5000 SWT device (BTL Industries, USA).
Study: NCT05223712

Intervention type: OTHER
Intervention: Diagnostic Test: Chronic Kidney Diseases
Description: The development datasets were used to train the deep learning model, which was validated and tested by the other 4 datasets.

Intervention type: OTHER
Intervention: Diagnostic Test: Chronic Kidney Diseases
Description: The development datasets were used to train the deep learning model, which was validated and tested by the other 4 datasets.

Intervention type: OTHER
Intervention: Diagnostic Test: Chronic Kidney Diseases
Description: The development datasets were used to train the deep learning model, which was validated and tested by the other 4 datasets.

Intervention type: OTHER
Intervention: Diagnostic Test: Chronic Kidney Diseases
Description: The development datasets were used to train the deep learning model, which was validated and tested by the other 4 datasets.
Study: NCT05103735

Intervention type: DRUG
Intervention: Propofol
Description: awake neurosurgery under propofol-remifentanil sedation
Study: NCT03492268

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCMA-CART
Description: After a conditioning therapy, each patient will receive a treatment of BCMA-CART originated from their own peripheral blood mononuclear cells
Study: NCT06391931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cipepofol
Description: 0.6±0.2 mg/kg induce + 0.8 mg/kg/h maintain

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: 3.0 mg/kg induce + 5.0 mg/kg/h maintain
Study: NCT05004454

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bacillus subtilis BS50 spore preparation
Description: Subjects will consume 1 capsule containing 2x10⁹ CFU of a Bacillus subtilis BS50 spore preparation once daily for 42 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Subjects will consume 1 capsule containing maltodextrin once daily for 42 days.
Study: NCT05395273

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Game Ready cryocompression
Description: Cryotherapy on the coldest tolerable level and intermittend compression on the knee
Study: NCT06742983

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isobutyl cyanoacrylate
Description: Thin layers of a high viscosity isobutyl cyanoacrylate high viscous solution Thin layers of a high viscosity isobutyl cyanoacrylate high viscous solution

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chlorhexidine (0.2%)
Description: Chlorhexidine Digluconate 0.2%

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline (0.9% NaCl)
Description: Sodium chloride 0.9%
Study: NCT05534607

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ola Mau i ka Hula
Description: The first 3 months of the hula-based intervention program was designed and standardized as a culturally-based physical activity (PA) that includes 15 minutes of ADRD education and intervention orientation with 12 weeks of hula lessons.~These hula lessons consist of two 60-minute classes per week over 12 weeks. Each hula lesson will consist of 8 participants, providing them with the opportunity to engage-in this social support network.~For the remaining 5 months of the Ola Mau i ka Hula Program, hula lessons led by the kumu hula will be reduced to once a month for 60 min. In addition, the intervention group will meet with a community-peer educator weekly over this 5-month period. Each meeting will be 90 minutes in length with 60 minutes of hula practice following the same format as previous classes, and 30 minutes will cover the PILI Lifestyle Plan curriculum and cultural-based cognitive exercises, alternating weekly.
Study: NCT05275413

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: family-based mHealth Intervention
Description: The intervention consists of three versions: mother, father, and grandparent. The app consists of health information about pregnancy, postnatal care, and infant care in the form of brief texts and short videos. Each versions have their unique features, such as a platform to ask questions in mother version, a quiz game to promote fathers' knowledge related to father's involvement, educational materials tailored for grandparents. An obstetrician and a social worker will respond to the questions. Details please refer to the proposal.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mother-only mHealth Intervention
Description: The expectant mothers in this group will receive information about pregnancy, postnatal care, and infant care in the form of brief texts and short videos via a smartphone app. The expectant mothers will also have access to a platform in the smartphone app to ask questions about their pregnancy. An obstetrician will respond to the questions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health education
Description: The expectant mothers in the control group will receive information about pregnancy, postnatal care, and infant care in the form of brief texts and short videos via a smartphone app.
Study: NCT06741631

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyPEEPS Mobile
Description: An evidence-based, digitally delivered mHealth sexual risk reduction intervention on HIV incidence.
Study: NCT06743048

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Tissue Sparing Laser Implantation
Description: A penile implant will be implanted using the cavernosal sparing technique and assisted by a laser fibre optic
Study: NCT06742515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab plus Reduced-dose Chemotherapy
Description: Cycle 1: Reduced VCP on day1, IV and Blinatumomab for 2 weeks, IV. Cycle 2: Blinatumomab for 2 weeks, IV and Venetoclax for 2 weeks, oral.
Study: NCT06741943

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: insulin pump (model: AR-B200A)
Description: USE insulin pump (model: AR-B200A) and continuous glucose monitoring (FreeStyle Libre)
Study: NCT06741787

Intervention type: DRUG
Intervention: Patients desensitized by sublingual spray
Description: Drug: Oraltekzc®️(Canis familiari), Oraltek®️(Felis domesticus), Oraltek®️(Alternaria alternata), dosage form: sublingual spray.
Study: NCT06742476

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nasal cannula
Description: In the apneic oxygenation group, nasal cannula will be employed to administer continuous oxygenation, utilizing a flow rate of 0.2 L/kg, during the apneic phase while tracheal intubation is performed. Successful intubation will be confirmed by auscultation and the appearance of a square wave capnogragh.